Silence Therapeutics Share Discussion Threads

[1gw] 09/1/2017 11:43

Amgen is backing Arrowhead, having bought in at end-September, just before the Arrowhead year-end. Arrowhead paid a lot more than Silence for the shares, paying $7.16 for the 3m shares it bought (price given in Arrowhead 10-K).

[1gw] 09/1/2017 11:16

I've bought some more on the back of that announcement.

I think there's a very positive statement on market value from AM in there "We believe that the recent technological advancements in RNA therapeutics have been underestimated and undervalued."

Arrowhead stock looks to be up over 20% in the pre-market, so the pyjama traders seem to be viewing this as a precursor to acquisition, but the Arrowhead market cap is quite a bit bigger than Silence's by my calcs, even at Friday's close price.

I wonder if Silence are looking to get a licensing deal out of this - i.e. if this is one of the companies that it thinks might need to use one of its patents.

If we are headed for consolidation then the Silence stake may end up being bought out by a bigger player who is looking to buy Arrowhead, so there's some option value in there as well.

[waterloo01] 09/1/2017 10:45

Two wrong don't make a right in my view. Arrowhead lost $80m last year alone. But who knows.

[richie666] 09/1/2017 10:28

Waterloo - clearly a precursor to a combine between the 2. Universally positive to me.

[waterloo01] 09/1/2017 07:23

Does anyone follow this? Beyond saying they have limited confidence in their own platform, what on earth is this about? Back to scatter guns probably. Not one for me.

[ukeagle2aus] 11/12/2016 23:30

Thanks Rogen8, I guess I can call myself patient after over a decade of holding SRP/SLN.

Said a few years back, in the bottom drawer and hopefully one day they'll deliver the goods in this field.

Wait on some more it is then.

[rogen83] 09/12/2016 23:18

Waterloo posted cautious comments on the SUMM board before the shares doubled. SLN have a good management team and experience board, it's a waiting game

[ukeagle2aus] 09/12/2016 12:38

OMG been a long time since I have been here and still a couple of handles I recognise.

I still hold these in the bottom drawer from well before the heady days before I left for down under (9 years ago).

Kept a small eye out and really dont know what is going on/outlook etc, but hopefully something will turn up eventually. Good luck all.

Eag

[callumross] 30/11/2016 13:53

Thanks for this Waterloo but you could actually look at this as a positive for SLN in that the failure of their delivery mechanism just highlights the proven track record safety profile of SLN's delivery mechanisms.

[gersemi] 15/11/2016 07:34

'Silence has confirmed the potential of its delivery platform for in vivo gene editing'...

looks like a leap forward for Silence. Certainly very good news indeed

[1gw] 15/11/2016 07:29

A bit technical for me, but that RNS sounds like good news...

[1gw] 06/10/2016 18:37

I don't think I'll be running just yet.

"Safety problems have not shown up to date in the company's other RNAi drugs, which are all delivered into patients differently from revusiran, Maraganore said. He added that he still expects to have three drugs approved and on the market by 2020."

... but certainly a reminder of the other side of the coin for biotech from the SUMM experience.

[1gw] 05/10/2016 13:51

Decent volume today. Are we getting a bit of the SUMM slipstream?

[1gw] 04/10/2016 15:43

Well that's why we buy into biotech I suppose - hoping to get a new treatment through to commercialisation or have someone with deep pockets buy in to help progress a potential treatment. SLN's turn may come...

In the meantime it can't do any harm to have a reminder of what can happen.

[callumross] 04/10/2016 13:28

Looking at todays announcement from SUMM, doesn't it just make you envious. Surely our turn will come!

[callumross] 29/9/2016 15:46

Canaccord Genuity today reaffirms its buy investment rating on Silence Therapeutics PLC (LON:SLN) and raised its price target to 249p (from 233p).

[1gw] 27/9/2016 12:16

I asked Ali M about the risk of costly legal battles at the AGM given the annual report statement that "the Company has received advice from three separate law firms indicating that the issued claims potentially capture other development stage siRNA candidates" as well as the disagreement over the milestone payment with Quark.

I got the impression from him that the "legal opinions" statement wasn't as bad as it sounded (to me) and that this was largely a due diligence move to strengthen the case for seeking licensing fees as a result of the new patent granted. I can't remember the detail but I think perhaps the reason for "several" opinions is that there are several drugs they are hoping to bring within scope of their patents.

And I am pleased to see from today's statement that the Quark issue has gone to arbitration rather than litigation.

[waterloo01] 27/9/2016 09:41

Long wavelength is right. Never liked Quark (and SLN seem to have a few issues as well) and talk of favourable legal opinions says to me they will have some court cases to fight. Nothing substantial in trials. I'll leave you with your deep base resonance.

[1gw] 27/9/2016 09:19

It's a fairly long wavelength business though, isn't it? I don't think we should expect to see dramatic new developments every few months. Even so, the section on licensing looks pretty positive to me:

"In December 2015, the Company had a further patent (9,222,092) granted in the US, which substantially broadens its position in modified siRNA molecules and we continue to seek additional granted claims through a program of continuation filings.

In the past six months Silence has obtained several favourable legal opinions indicating that multiple siRNA based drugs currently in clinical development potentially fall within its issued claims. Subsequently, the Company has invited the relevant companies to enter licensing negotiations.

The strengthened position around AtuRNAi® makes this asset an even more significant value driver, comprising existing licensee Quark’s clinical progress, ongoing negotiations and potential additional licences."

[waterloo01] 27/9/2016 08:00

Seems like very little progress on any fronts since I last looked a year ago.

[waterloo01] 26/9/2016 16:10

Not in anymore, but has that much changed when aut027 was/is the companies lead and main trial? Never liked it when they went for combo.